Arylesterase activity of paraoxonase 1 in patients with primary hypertension

[1]Brzyżkiewicz H., Konduracka E., Gajos G., Janion M.: Incidence of chronic heart failure with preserved left ventricular ejection fraction in patients with hypertension and isolated mild diastolic dysfunction. Pol. Arch. Med. Wewn., 2016; 126: 12–18.Brzyżkiewicz H. Konduracka E. Gajos G. Janion M. Incidence of chronic heart failure with preserved left ventricular ejection fraction in patients with hypertension and isolated mild diastolic dysfunction Pol. Arch. Med. Wewn 2016 126 12 1810.20452/pamw.3257Search in Google Scholar

[2]Czarnecka D., Jankowski P., Kopeć G., Pająk A., Podolec J., Zdrojewski T., Drygas W., Małecki M., Nowicka G., Windak A., et al.: Polish Forum for Prevention Guidelines on Hypertension: Update 2017. Kardiol. Pol., 2017; 75: 282–285.Czarnecka D. Jankowski P. Kopeć G. Pająk A. Podolec J. Zdrojewski T. Drygas W. Małecki M. Nowicka G. Windak A. et al Polish Forum for Prevention Guidelines on Hypertension: Update 2017 Kardiol. Pol 2017 75 282 28510.5603/KP.2017.005528326530Search in Google Scholar

[3]Eren E., Yilmaz N., Aydin O., Ellidağ H.Y.: Anticipatory role of high density lipoprotein and endothelial dysfunction: An overview. Open. Biochem. J., 2014; 8: 100–106.Eren E. Yilmaz N. Aydin O. Ellidağ H.Y. Anticipatory role of high density lipoprotein and endothelial dysfunction: An overview Open. Biochem. J 2014 8 100 10610.2174/1874091X01408010100429374225598849Search in Google Scholar

[4]Banaszewska A., Baszczuk A., Kopczyński Z., Thielemann A., Kopczyński P.: The role of paraoxonase 1 (EC 3.1.8.1) in the development of atherosclerosis. Post. Biol. Kom., 2014; 41: 429–444.Banaszewska A. Baszczuk A. Kopczyński Z. Thielemann A. Kopczyński P. The role of paraoxonase 1 (EC 3.1.8.1) in the development of atherosclerosis Post. Biol. Kom 2014 41 429 444Search in Google Scholar

[5]Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parrno S.L., La Du B.N.: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest., 1998; 101: 1581–1590.Aviram M. Rosenblat M. Bisgaier C.L. Newton R.S. Primo-Parrno S.L. La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions A possible peroxidative role for paraoxonase. J. Clin. Invest 1998 101 1581 159010.1172/JCI1649Search in Google Scholar

[6]Hine D., Mackness B., Mackness M.: Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life, 2012; 64: 157–161.Hine D. Mackness B. Mackness M. Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation IUBMB Life 2012 64 157 16110.1002/iub.58822184096Search in Google Scholar

[7]Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J.: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature, 1998; 394: 284–287.Shih D.M. Gu L. Xia Y.R. Navab M. Li W.F. Hama S. Castellani L.W. Furlong C.E. Costa L.G. Fogelman A.M. Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 1998 394 284 28710.1038/284069685159Search in Google Scholar

[8]Tavori M., Aviram S., Khatib S., Musa R., Nitecki S., Hoffman A., Vaya J.: Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic. Biol. Med., 2009; 46: 607–615.Tavori M. Aviram S. Khatib S. Musa R. Nitecki S. Hoffman A. Vaya J. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects Free Radic. Biol. Med 2009 46 607 61510.1016/j.freeradbiomed.2008.11.01919103284Search in Google Scholar

[9]Shunmoogam N., Naidoo P., Chilton R.: Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc. Health Risk Manag., 2018; 14: 137-143.Shunmoogam N. Naidoo P. Chilton R. Paraoxonase (PON)-1: A brief overview on genetics, structure, polymorphisms and clinical relevance Vasc. Health Risk Manag 2018 14 137 14310.2147/VHRM.S165173601438929950852Search in Google Scholar

[10]Zhao Y., Ma Y., Fang Y., Liu L., Wu S., Fu D., Wang X.: Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies. Mol. Genet. Metab., 2012; 105: 141–148.Zhao Y. Ma Y. Fang Y. Liu L. Wu S. Fu D. Wang X. Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies Mol. Genet. Metab 2012 105 141 14810.1016/j.ymgme.2011.09.01822030099Search in Google Scholar

[11]Kunutsor S.K., Bakker S.J., James R.W., Dullaart R.P.: Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis, 2016; 245: 143–154.Kunutsor S.K. Bakker S.J. James R.W. Dullaart R.P. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies Atherosclerosis 2016 245 143 15410.1016/j.atherosclerosis.2015.12.02126724525Search in Google Scholar

[12]Zhou C., Cao J., Shang L., Tong C., Hu H., Wang H., Fan D., Yu H.: Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis. Markers, 2013; 35: 97–103.Zhou C. Cao J. Shang L. Tong C. Hu H. Wang H. Fan D. Yu H. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease Dis. Markers 2013 35 97 10310.1155/2013/816189377497424167353Search in Google Scholar

[13]Michalak S., Ambrosius W., Wysocka E., Dziarmaga M., Juszkat R., Wykretowicz A., Kozubski W.: The early effect of carotid artery stenting on antioxidant capacity and oxidative stress in patients with carotid artery stenosis. Oxid. Med. Cell. Longev., 2016; 2016: 1789596.Michalak S. Ambrosius W. Wysocka E. Dziarmaga M. Juszkat R. Wykretowicz A. Kozubski W. The early effect of carotid artery stenting on antioxidant capacity and oxidative stress in patients with carotid artery stenosis Oxid. Med. Cell. Longev 2016 2016 178959610.1155/2016/1789596518747728058087Search in Google Scholar

[14]Chen X., Wu Y., Liu L., Su Y., Peng Y., Jiang L., Liu X., Huang D.: Relationship between high density lipoprotein antioxidant activity and carotid arterial intima-media thickness in patients with essential hypertension. Clin. Exp. Hypertens., 2010; 32: 13–20.Chen X. Wu Y. Liu L. Su Y. Peng Y. Jiang L. Liu X. Huang D. Relationship between high density lipoprotein antioxidant activity and carotid arterial intima-media thickness in patients with essential hypertension Clin. Exp. Hypertens 2010 32 13 2010.3109/1064196090292948720144068Search in Google Scholar

[15]Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D.M., Chroni A., Yonekawa K., Stein S., Schaefer N., et al.: Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest., 2011; 121: 2693–2708.Besler C. Heinrich K. Rohrer L. Doerries C. Riwanto M. Shih D.M. Chroni A. Yonekawa K. Stein S. Schaefer N. et al Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J. Clin. Invest 2011 121 2693 270810.1172/JCI42946322381721701070Search in Google Scholar

[16]Xu S., Ogura S., Chen J., Little P.J., Moss J., Liu P.: LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers. Cell. Mol. Life Sci., 2013; 70: 2859–2872.Xu S. Ogura S. Chen J. Little P.J. Moss J. Liu P. LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers Cell. Mol. Life Sci 2013 70 2859 287210.1007/s00018-012-1194-z414204923124189Search in Google Scholar

[17]Charakida M., Besler C., Batuca J.R., Sangle S., Marques S., Sousa M., Wang G., Touisoulis D., Alves J.D., Loukogeorgakis S.P., et al.: Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA, 2009; 302: 1210–1217.Charakida M. Besler C. Batuca J.R. Sangle S. Marques S. Sousa M. Wang G. Touisoulis D. Alves J.D. Loukogeorgakis S.P. et al Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome JAMA 2009 302 1210 121710.1001/jama.2009.134619755700Search in Google Scholar

[18]Adams V., Besler C., Fischer T., Riwanto M., Noack F., Höllriegel R., Oberbach A., Jehmlich N., Völker U., Winzer E.B., et al.: Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ. Res., 2013; 113: 1345–1355.Adams V. Besler C. Fischer T. Riwanto M. Noack F. Höllriegel R. Oberbach A. Jehmlich N. Völker U. Winzer E.B. et al Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties Circ. Res 2013 113 1345 135510.1161/CIRCRESAHA.113.30168424055733Search in Google Scholar

[19]Ayashi S., Assareh A.R., Jalali M.T., Olapour S., Yaghooti H.: Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study. Indian. J. Pharmacol., 2016; 48: 372–376.Ayashi S. Assareh A.R. Jalali M.T. Olapour S. Yaghooti H. Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study Indian. J. Pharmacol 2016 48 372 37610.4103/0253-7613.186206498092327756946Search in Google Scholar

[20]Fridman O., Gariglio L., Riviere S., Porcile R., Fuchs A., Potenzoni M.: Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia. Arch. Cardiol. Mex., 2016; 86: 350–357.Fridman O. Gariglio L. Riviere S. Porcile R. Fuchs A. Potenzoni M. Paraoxonase 1 gene polymorphisms and enzyme activities in coronary artery disease and its relationship to serum lipids and glycemia Arch. Cardiol. Mex 2016 86 350 35710.1016/j.acmx.2016.08.00127640339Search in Google Scholar

[21]Rybka J., Kupczyk D., Kędziora-Kornatowska K., Motyl J., Czuczejko J., Szewczyk-Golec K., Kozakiewicz M., Pawluk H., Carvalho L.A., Kędziora J.: Glutathione-related antioxidant defense system in elderly patients treated for hypertension. Cardiovasc. Toxicol., 2011; 11: 1–9.Rybka J. Kupczyk D. Kędziora-Kornatowska K. Motyl J. Czuczejko J. Szewczyk-Golec K. Kozakiewicz M. Pawluk H. Carvalho L.A. Kędziora J. Glutathione-related antioxidant defense system in elderly patients treated for hypertension Cardiovasc. Toxicol 2011 11 1 910.1007/s12012-010-9096-5303577521140238Search in Google Scholar

[22]Mineo C., Shaul P.W.: PON-dering differences in HDL function in coronary artery disease. J. Clin. Invest., 2011; 121: 2545–2548.Mineo C. Shaul P.W. PON-dering differences in HDL function in coronary artery disease J. Clin. Invest 2011 121 2545 254810.1172/JCI57671322384421701074Search in Google Scholar

[23]Rahmani M., Raiszadeh F., Allahverdian S., Kiaii S., Navab M., Azizi F.: Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis, 2002; 162: 381–389.Rahmani M. Raiszadeh F. Allahverdian S. Kiaii S. Navab M. Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects Atherosclerosis 2002 162 381 38910.1016/S0021-9150(01)00715-8Search in Google Scholar

[24]Göçmen A.Y., Gümüşlü S., Semiz E.: Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin. Cardiol., 2004; 27: 426–430.Göçmen A.Y. Gümüşlü S. Semiz E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease Clin. Cardiol 2004 27 426 43010.1002/clc.4960270714665420015298047Search in Google Scholar

[25]Shekhanawar M., Shekhanawar S.M., Krisnaswamy D., Indumati V., Satishkumar D., Vijay V., Rajeshwari T., Amareshwar M.: The role of “paraoxonase-1 activity” as an antioxidant in coronary artery diseases. J. Clin. Diagn. Res., 2013; 7: 1284–1287.Shekhanawar M. Shekhanawar S.M. Krisnaswamy D. Indumati V. Satishkumar D. Vijay V. Rajeshwari T. Amareshwar M. The role of “paraoxonase-1 activity” as an antioxidant in coronary artery diseases J. Clin. Diagn. Res 2013 7 1284 128710.7860/JCDR/2013/5144.3118374961623998046Search in Google Scholar

[26]Yan L.R., Wang D.X., Liu H., Zhang X.X., Zhao H., Hua L., Xu P., Li Y.S.: A pro-atherogenic HDL profile in coronary heart disease patients: An iTRAQ labelling-based proteomic approach. PLoS One, 2014; 9: e98368.Yan L.R. Wang D.X. Liu H. Zhang X.X. Zhao H. Hua L. Xu P. Li Y.S. A pro-atherogenic HDL profile in coronary heart disease patients: An iTRAQ labelling-based proteomic approach PLoS One 2014 9 e9836810.1371/journal.pone.0098368403233224859250Search in Google Scholar

[27]Alaminos-Castillo M.Á., Ho-Pagaro A., García-Serrano S., Santiago-Fernandez C., Rodríguez-Pacheco F., Garrido-Sanchez L., Rodriguez C., Valdes S., Gonzalo M., Moreno-Ruiz F.J., et al.: Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile. Int. J. Clin. Pract., 2019; 73: e13315.Alaminos-Castillo M.Á. Ho-Pagaro A. García-Serrano S. Santiago-Fernandez C. Rodríguez-Pacheco F. Garrido-Sanchez L. Rodriguez C. Valdes S. Gonzalo M. Moreno-Ruiz F.J. et al Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile Int. J. Clin. Pract 2019 73 e1331510.1111/ijcp.1331530681756Search in Google Scholar

[28]Aslan M., Horoz M., Sabuncu T., Celik H., Selek S.: Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol. Arch. Med. Wewn., 2011; 121: 181–186.Aslan M. Horoz M. Sabuncu T. Celik H. Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects Pol. Arch. Med. Wewn 2011 121 181 18610.20452/pamw.1051Search in Google Scholar

[29]van Himbergen T.M., Roest M., de Graaf J., Jansen E.H., Hattori H., Kastelein J.J., Voorbij H.A., Stalenhoef A.F., van Tits L.J.: Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J. Lipid Res., 2005; 46: 445-451.van Himbergen T.M. Roest M. de Graaf J. Jansen E.H. Hattori H. Kastelein J.J. Voorbij H.A. Stalenhoef A.F. van Tits L.J. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia J. Lipid Res 2005 46 445 45110.1194/jlr.M400052-JLR20015576850Search in Google Scholar

[30]Daly C., Fitzgerald A.P., O’Callaghan P., Collins P., Cooney M.T., Graham I.M., COMAC Group.: Homocysteine increases the risk associate with hyperlipidaemia. Eur. J. Cardiovasc. Prev. Rehabil., 2009; 16: 150–155.Daly C. Fitzgerald A.P. O’Callaghan P. Collins P. Cooney M.T. Graham I.M. COMAC Group. Homocysteine increases the risk associate with hyperlipidaemia Eur. J. Cardiovasc. Prev. Rehabil 2009 16 150 15510.1097/HJR.0b013e32831e118519276985Search in Google Scholar

[31]Guéant-Rodriguez R.M., Spada R., Moreno-Garcia M., Anello G., Bosco P., Lagrost L., Romano A., Elia M., Guéant J.L.: Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis, 2011; 214: 480–485.Guéant-Rodriguez R.M. Spada R. Moreno-Garcia M. Anello G. Bosco P. Lagrost L. Romano A. Elia M. Guéant J.L. Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population Atherosclerosis 2011 214 480 48510.1016/j.atherosclerosis.2010.11.03121156318Search in Google Scholar

[32]Baszczuk A., Musialik K., Kopczyński J., Thielemann A., Kopczyński Z., Kęsy L., Dopierała G.: Hyperhomocysteinemia, lipid and lipoprotein disturbances in patients with primary hypertension. Adv. Med. Sci., 2014; 59: 68–73.Baszczuk A. Musialik K. Kopczyński J. Thielemann A. Kopczyński Z. Kęsy L. Dopierała G. Hyperhomocysteinemia, lipid and lipoprotein disturbances in patients with primary hypertension Adv. Med. Sci 2014 59 68 7310.1016/j.advms.2013.08.00124797978Search in Google Scholar

[33]Ferretti G., Bacchetti T., Marotti E., Curatola G.: Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity. Metabolism, 2003; 52: 146–151.Ferretti G. Bacchetti T. Marotti E. Curatola G. Effect of homocysteinylation on human high-density lipoproteins: A correlation with paraoxonase activity Metabolism 2003 52 146 15110.1053/meta.2003.5003312601623Search in Google Scholar

[34]Liao D., Tan H., Hui R.,, Li Z., Jiang X., Gaubatz J., Yang F., Durante W., Chan L., Schafer A.I., et al.: Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ. Res., 2006; 99: 598–606.Liao D. Tan H. Hui R.Li Z. Jiang X. Gaubatz J. Yang F. Durante W. Chan L. Schafer A.I. et al Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance Circ. Res 2006 99 598 60610.1161/01.RES.0000242559.42077.22440084116931800Search in Google Scholar

[35]Perła-Kaján J., Jakubowski H.: Paraoxonase 1 and homocysteine metabolism. Amino Acids, 2012; 43: 1405–1417.Perła-Kaján J. Jakubowski H. Paraoxonase 1 and homocysteine metabolism Amino Acids 2012 43 1405 141710.1007/s00726-012-1321-z22643843Search in Google Scholar

[36]Locsey L., Seres I., Sztanek F., Harangi M., Padra J., Kovacs D., Fedor R., Asztalos L., Paragh G.: Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients. Transplant. Proc., 2013; 45: 3685–3687.Locsey L. Seres I. Sztanek F. Harangi M. Padra J. Kovacs D. Fedor R. Asztalos L. Paragh G. Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients Transplant. Proc 2013 45 3685 368710.1016/j.transproceed.2013.10.00324314997Search in Google Scholar

[37]Karikas G.A., Kriebardis A., Samara I., Schulpis K., Papachristodoulou M., Fytou-Pallikari A.: Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin. Chem. Lab. Med., 2006; 44: 623–627.Karikas G.A. Kriebardis A. Samara I. Schulpis K. Papachristodoulou M. Fytou-Pallikari A. Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece Clin. Chem. Lab. Med 2006 44 623 62710.1515/CCLM.2006.11016681435Search in Google Scholar

[38]Holven K.B., Aukrust P., Retterstøl K., Otterdal K., Bjerkeli V., Ose L., Nenseter M.S., Halvorsen B.: The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J. Nutr., 2008; 138: 2070–2075.Holven K.B. Aukrust P. Retterstøl K. Otterdal K. Bjerkeli V. Ose L. Nenseter M.S. Halvorsen B. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects J. Nutr 2008 138 2070 207510.3945/jn.108.09070418936200Search in Google Scholar

[39]Tang W.H., Hartiala J., Fan Y., Wu Y., Stewart A.F., Erdmann J., Kathiresan S., CARDIoGRAM Consortium, Roberts R., McPherson R., et al.: Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler. Thromb. Vasc. Biol., 2012; 32: 2803–2812.Tang W.H. Hartiala J. Fan Y. Wu Y. Stewart A.F. Erdmann J. Kathiresan S. CARDIoGRAM Consortium Roberts R. McPherson R. et al Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk Arterioscler. Thromb. Vasc. Biol 2012 32 2803 281210.1161/ATVBAHA.112.253930349994622982463Search in Google Scholar

[40]Abelló D., Sancho E., Camps J., Joven J.: Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: A systematic review. Int. J. Mol. Sci., 2014; 15: 20997–21010.Abelló D. Sancho E. Camps J. Joven J. Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: A systematic review Int. J. Mol. Sci 2014 15 20997 2101010.3390/ijms151120997426420825405733Search in Google Scholar